艾伯维公司近日宣布,其评估Skyrizi®(利生奇单抗)皮下诱导方案用于克罗恩病患者的第三阶段Affirm研究取得了积极的顶线结果。该研究达到了其主要终点,显示出显著的治疗效果。
这一突破性进展为克罗恩病患者提供了新的潜在治疗选择,进一步巩固了Skyrizi®在自身免疫性疾病治疗领域的地位。
艾伯维公司近日宣布,其评估Skyrizi®(利生奇单抗)皮下诱导方案用于克罗恩病患者的第三阶段Affirm研究取得了积极的顶线结果。该研究达到了其主要终点,显示出显著的治疗效果。
这一突破性进展为克罗恩病患者提供了新的潜在治疗选择,进一步巩固了Skyrizi®在自身免疫性疾病治疗领域的地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.